Optimus Drugs Profile
Key Indicators
- Authorised Capital ₹ 410.00 Cr
as on 23-11-2024
- Paid Up Capital ₹ 37.14 Cr
as on 23-11-2024
- Company Age 21 Year, 20 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 188.61 Cr
as on 23-11-2024
- Satisfied Charges ₹ 167.44 Cr
as on 23-11-2024
- Revenue 1.98%
(FY 2023)
- Profit -109.56%
(FY 2023)
- Ebitda 22.97%
(FY 2023)
- Net Worth 119.21%
(FY 2023)
- Total Assets 73.35%
(FY 2023)
About Optimus Drugs
The Corporate was formerly known as Surya Kiran Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 410.00 Cr and a paid-up capital of Rs 37.14 Cr.
The company currently has active open charges totaling ₹188.61 Cr. The company has closed loans amounting to ₹167.44 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Optimus Drugs Private Limited India is Ritali Tangudu as COMPANY SECRETARY. Srinivasareddy Desireddy, Uma Rao, Anil Khubchandani, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239TG2003PTC042155
- Company No.
042155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2003
- Date of AGM
21 Oct 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Optimus Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ritali Tangudu | Company Secretary | 22-Jul-2022 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uma Rao  | Additional Director | 09-May-2024 | Current |
| Srinivasareddy Desireddy | Director | 30-Mar-2006 | Current |
| Anil Khubchandani | Director | 26-Jun-2023 | Current |
| Durga Avula | Director | 22-Sep-2022 | Current |
| Pagadala Baskarannarayanan | Director | 19-Oct-2022 | Current |
Financial Performance of Optimus Drugs.
Optimus Drugs Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.98% increase. The company also saw a substantial fall in profitability, with a 109.56% decrease in profit. The company's net worth Soared by an impressive increase of 119.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Optimus Drugs?
In 2023, Optimus Drugs had a promoter holding of 99.98% and a public holding of 0.02%. The company had 2 Subsidiaries. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Optimus Pharma Private LimitedActive 20 years 3 monthsSrinivasareddy Desireddy, Uma Rao and 3 more are mutual person
- Optimus Life Science Private LimitedActive 4 years 9 months
Uma Rao, Anil Khubchandani and 1 more are mutual person
Anjan Drug Private LimitedActive 34 years 4 monthsAnil Khubchandani and Pagadala Baskarannarayanan are mutual person
- Orygamus Laboratories Private LimitedActive 8 years 10 months
Srinivasareddy Desireddy is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 11 Nov 2022 | ₹3.61 Cr | Open |
Hdfc Bank Limited Creation Date: 10 May 2022 | ₹1.00 Cr | Open |
Hdfc Bank Limited Creation Date: 16 Sep 2017 | ₹55.00 Cr | Open |
How Many Employees Work at Optimus Drugs?
Optimus Drugs has a workforce of 699 employees as of Nov 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Optimus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Optimus Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
